Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide + Cetuximab in KRAS Mutant Metastatic Colorectal Cancer
NCT01032291Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Dec 2009
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of lenalidomide in colorectal cancer (CRC), sponsored by Celgene Corporation. Started Dec 2009; status: terminated.
02
Drugs
lenalidomide
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01032291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01032291.